Session: Interactive Symposium: Update on the Antifungal Formulary
Tuesday, October 28, 2008: 12:00 AM
Room: Ballroom C
John Rex, MD, AstraZeneca, Macclesfield Cheshire, United Kingdom and J. Rex, AstraZeneca PharmaceuticalsRole(s): Employee, Employee, Employee, Received: Salary.
John H. Rex, MD received his MD degree from Baylor College of Medicine (1982), trained in Internal Medicine at Stanford University Hospital (1984-1987), and trained in Infectious Diseases at the National Institute of Allergy and Infectious Diseases (1987-1992). Dr. Rex served on the faculty of the University of Texas Medical School at Houston from 1992-2002 during which time his work focused on laboratory studies of novel antifungal agents, clinical trials of novel antifungal agents, and hospital epidemiology. In 2003, Dr. Rex moved to AstraZeneca Pharmaceuticals where he currently serves as Vice President Clinical Infection. In this role, Dr. Rex leads AstraZeneca’s efforts to develop a portfolio of novel antibacterial, antimycobacterial, and antiviral agents. Dr. Rex sits on the US FDA Anti-Infective Drug Advisory Committee, is the Vice-Chair of the Area Committee on Microbiology for the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS), is an Editor for Antimicrobial Agents and Chemotherapy, is a Highlights Advisor for Nature Reviews Microbiology, and serves on several editorial boards, is an Emeritus Editor for www.doctorfungus.org, a non-profit web site devoted to dissemination of information about medical mycology.